CLINICAL TRIALS PROFILE FOR NATEGLINIDE
✉ Email this page to a colleague
All Clinical Trials for nateglinide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00097786 ↗ | Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications | Completed | Novartis Pharmaceuticals | Phase 3 | 2002-01-01 | This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking. |
| NCT00189774 ↗ | Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients | Completed | Ajinomoto USA, INC. | Phase 2/Phase 3 | 1969-12-31 | The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment. |
| NCT00189774 ↗ | Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients | Completed | Astellas Pharma Inc | Phase 2/Phase 3 | 1969-12-31 | The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment. |
| NCT00212290 ↗ | Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 4 | 2002-11-01 | The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid. |
| NCT00238472 ↗ | A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion | Completed | Novartis Pharmaceuticals | Phase 4 | 2003-05-01 | This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion. |
| NCT00259168 ↗ | Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? | Completed | Bayer | Phase 4 | 2003-06-01 | The purpose of this study is to determine whether attenuation/normalization of elevated blood sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin resistance. |
| NCT00259168 ↗ | Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? | Completed | Novartis | Phase 4 | 2003-06-01 | The purpose of this study is to determine whether attenuation/normalization of elevated blood sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin resistance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for nateglinide
Condition Name
Clinical Trial Locations for nateglinide
Trials by Country
Clinical Trial Progress for nateglinide
Clinical Trial Phase
Clinical Trial Sponsors for nateglinide
Sponsor Name
